| Date | Title | Description |
| 21.11.2021 | Sofinnova Partners Raises €150M for Its Third Industrial Biotech Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, raised €150m for its third Industrial Biotech Fund.
Sofinnova Industrial Biotech II, which brought the firm’s total assets under management to €2.5 b... |
| 17.11.2021 | VC firm Sofinnova Partners secures €150M to invest in companies leveraging biotech to develop sustainable solutions | Paris-based Sofinnova Partners, a venture capital firm that invests in the life sciences sector from Seed to later-stage, announced that it has secured €150M for its third industrial biotech fund dedicated to environmental impact. With this... |
| 26.10.2021 | Sofinnova Partners Congratulates Portfolio Company DNA Script for the Success of Its 142M ($165M) Oversubscribed Series C Fundraise | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its portfolio company DNA Script has raised €142 million ($165 million) in a Series C financing led by top glob... |
| 25.10.2021 | Sofinnova Partners Raises €472M to Form Early-Stage Healthcare VC Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, at €472 ($548) million.
Capital X, the 10th iteration of Sofinnov... |
| 19.10.2021 | Sofinnova Partners : Raises 472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at €472 ($5... |
| 19.10.2021 | European Life Sciences Investor Sofinnova Partners Raises $548 Million | European venture-capital firm Sofinnova Partners has raised €472 million, equivalent to $548 million, to invest in life sciences startups, the latest in a series of healthcare funds the firm has closed recently.
Sofinnova, based in Paris, L... |
| 19.07.2021 | Sofinnova Partners Closes €63M Medtech Acceleration Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, closed its medtech acceleration fund, at €63m ($75m USD).
Sofinnova MD Start III enables Sofinnova MD Start’s pioneering team of serial entr... |
| 13.07.2021 | Sofinnova Partners nets $75M for third medtech accelerator fund
Are Real-time Gene Therapy Results Possible? | Shortly after raising an oversubscribed €445 million ($540 million) capital round to support clinical-stage healthcare companies, Sofinnova Partners is back to announce it has gathered €63 million ($75 million) for the final closure of its ... |
| 13.07.2021 | Sofinnova Partners : Closes 63M ($75M) Oversubscribed Medtech Acceleration Fund | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of its medtech acceleration fund, Sofinnova MD Start III, at €63 million ($75 million USD). The fund... |
| 04.03.2021 | London VC Sofinnova Partners pulls in £384M funding to help European clinical-stage companies | The life science industry is entering its next S-curve of growth as various companies are working towards innovations and advancements to create a sustainable environment.
Notably, the cash burns in this industry especially for clinical tri... |
| 03.03.2021 | Sofinnova Partners raises $540m | - |
| 03.03.2021 | Sofinnova Partners closes crossover fund at €445 Million | Paris, London and Milan-based Sofinnova Partners has recently announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million. This now comprises the largest crossover investor dedicated late-stage biophar... |
| 03.03.2021 | Sofinnova Partners Closes €445M Late-Stage Healthcare Crossover Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, closed Sofinnova Crossover Fund at €445m ($540m USD).
Led by Cédric Moreau, Partner, the Sofinnova Crossover Fund will maintain its focus on... |
| 03.03.2021 | European VC Sofinnova Partners raises $540M late-stage crossover healthcare fund
W e b i n a r
The role of clinical adjudication in trial efficiency and data quality for interstitial lung disease (I... | Sofinnova Partners has pulled in a healthy €445 million ($540 million) in its latest capital raise as the European venture capital firm seeks out late-stage plays in biotech and medtech.
BD&L Summit
Deal-Making Insights for the Life Sci... |
| 17.10.2019 | Sofinnova Partners Closes Early-Stage Healthcare Fund, at €333M | Sofinnova Partners, a Paris, France-based venture capital firm focused on life sciences, closed its latest early-stage healthcare fund, Sofinnova Capital IX, at €333m.
The new fund has commitments from leading institutional investors, predo... |
| 21.05.2019 | Sofinnova Partners Closes Medtech Acceleration Fund, at €48M | Sofinnova Partners, a European venture capital firm specialized in Life Sciences, closed its third medtech acceleration fund, at €48M.
MD Start III, which closed above its original target of €40m, received support from returning investors B... |
| 17.07.2018 | HotSpot Therapeutics Completes $45 Million Series A Financing | HotSpot Therapeutics, a new biotechnology company targeting nature's regulatory hotspots to discover and develop first-in-class medicines, today announced the completion of a $45 million Series A financing. "Regulatory hotspots" a... |
| 10.07.2018 | Sofinnova Partners Sells ReCor Medical to Otsuka Holdings | Sofinnova Partners, a Paris, France-based venture capital firm specialized in Life Sciences, announced the sale of its portfolio company ReCor Medical, a Palo Alto, CA and Sandwich, Kent, UK-based medical device company specialized in the t... |
| 21.05.2018 | Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner | Sofinnova Partners, a European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner.
As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical... |
| 04.04.2018 | Sofinnova Partners Launches New €275M Venture Capital Fund | Sofinnova Partners, a Paris, France–based venture capital firm specialized in Life Sciences, has launched Sofinnova Crossover I with €275m ($340m).
This new fund received support from sovereign funds, insurance companies, corporations and f... |
| 04.04.2018 | Sofinnova raises €275M crossover fund to back late-stage firms | Sofinnova Partners has raised a €275 million ($340 million) crossover fund. The vehicle sets Sofinnova up to expand beyond its traditional areas of focus and invest in 15 late-stage private and public drug and medical device companies.
Spon... |
| 12.03.2018 | Sofinnova Partners Closes €125M Fund Focused on Industrial Biotechnologies | Sofinnova Partners, a European venture capital firm specialized in life sciences, recently closed a €125M fund.
Financed by institutional investors and industrial players, Sofinnova IB I is dedicated to industrial biotechnologies, with a fo... |
| 06.03.2018 | Micropep Raises €4m Series A for miRNA-based Crop Enhancement | Micropep Technologies, a French ag biotechnology company, has raised a €4 million ($4.94 million) Series A round of funding. The round was led by Sofinnova Partners, a Paris-based life sciences investor with $1.5 billion under management. M... |
| 30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here’s a quick summary of what’s been going on: Bitcoin blew past the $9,000 per coin mark on Sunday. Then, all hell broke loo... |
| 29.11.2017 | Sofinnova Partners Appoints Maina Bhaman as Partner | Sofinnova Partners, a Life Sciences venture capital firm focused on Europe, has appointed Maina Bhaman as Partner.
Maina Bhaman comes to Sofinnova Partners with a long track record as a healthcare investor.
Prior to joining, she was Directo... |
| 22.05.2017 | Sofinnova Partners Appoints Graziano Seghezzi as Managing Partner | Sofinnova Partners, a Paris, France-based venture capital firm specialized in Life Sciences, has appointed Graziano Seghezzi as Managing Partner.
Seghezzi, who joined Antoine Papiernik, Denis Lucquin, and Monique Saulnier in the firm’s Mana... |
| 18.04.2017 | Why Securing Funds for Biotech Innovators is a ‘Different’ Challenge | Paris-based venture capital firm, Sofinnova Partners, has financed and accompanied almost 500 companies during its 45-year existence, including some in and around the agtech scene. Most recently the firm invested in AgroSavfe, a Belgian agr... |
| 29.03.2017 | Term Sheet — Wednesday, March 29 | IPOS ARE COOL AGAIN
For that reason, I’ve always thought the official end of the unicorn era would happen when the biggest, most valuable, most high profile and most quintessential billion-dollar startups, Airbnb and Uber, finally went publ... |
| 28.03.2017 | Sofinnova Partners Appoints Antoine Papiernik as Chairman | Sofinnova Partners, a European venture capital firm specialized in Life Sciences, appointed Antoine Papiernik as Chairman.
Papiernik, who succeeds Denis Lucquin who remains as a Managing Partner, joined Sofinnova Partners in 1997. He has a ... |
| 28.03.2017 | Papiernik named chairman at Sofinnova Partners; Cara shares surge on positive data for uremic pruritus | Antoine Papiernik
→ Twenty years after joining Sofinnova Partners in Paris, Antoine Papiernik is taking the chairman’s post. Papiernik is well known in VC circles on both sides of the Atlantic, and played a leading role inve... |
| 09.03.2017 | AgroSavfe Raises €11M in Series B Funding | AgroSavfe NV, a Ghent, Belgium-based agro-biotech company, extended its Series B financing round to €11m.
Sofinnova Partners joined earlier investors Agri Investment Fund, Biovest, Gimv, Globachem, Madeli Participaties, PMV, Qbic and VIB.
T... |
| 09.03.2017 | Belgian Startup Using Llama Antibodies for Biopesticides Increases Series B to $11.6m | AgroSavfe, a Belgian agro-biotech company that is developing a new generation of biopesticides, has increased its Series B financing round to $11.6 million. The bulk of the additional investment was provided by the Paris-based venture capit... |
| 03.03.2017 | Term Sheet — Friday, March 3 | SNAP, CRACKLE, POP
Good morning, Term Sheet readers. Today’s guest column, from Fortune writer Jen Wieczner, is a comprehensive look at the tech company on everyone’s tongues this week: Snap Inc.
Paid Content How can you protect what you ca... |
| 02.03.2017 | Sofinnova Partners Raises €106M in First Close of Industrial Biotech Fund | Sofinnova Partners, a Paris, France-based venture capital firm specialized in life sciences, held the first closing of its latest fund, at €106m.
Limited partners in Sofinnova Industrial Biotech I (Sofinnova IB I) included European institut... |
| 08.02.2017 | Lysogene raises $25M in Paris IPO; Chan Zuckerberg Biohub starts handing out $50M | Karen Aiach
• The gene therapy company Lysogene has raised $25 million from an IPO on Euronext Paris designed to fund its R&D work. “This IPO will enable us to pursue the development of two drugs to treat two polysdisabli... |
| 17.10.2016 | Sofinnova closes on $650 mln 10th fund, adds partner | - |
| 14.09.2016 | Sofinnova Partners and Atlas Venture Co-led $35 Million Series A for Delinia | CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Delinia, a new company developing novel therapeutics that rebalance the immune system to treat serious and life-threatening autoimmune diseases, announced today that it has closed a $35... |
| 08.04.2016 | Daily funding roundup - April 8, 2016 | Getui bagged $180M; Twiggle secured $12.5M; KiteDesk completed $6M funding round
RiskRecon landed seed-round financing led by General Catalyst Partners and several private investors. The funding will enable RiskRecon to expand its product d... |
| 17.03.2016 | Daily funding roundup - March 17, 2016 | 10x Genomics closed Series C funding; Momo obtained $28; Handshake secured $14M
Afluenta, a peer-to-peer lending platform based in Argentina, raised an $8 million round of funding from the International Finance Corporation (IFC) and Elevar ... |
| 08.12.2015 | Sofinnova Partners launches a €300M biotech startup fund with European focus | International investors, the majority from Europe, including France, Italy, Sweden, Norway, Switzerland, Belgium and Luxembourg, as well as from leading North American investors in the US and Canada contributed to the fund. Money primarily ... |
| 08.12.2015 | Sofinnova Partners Closes Fund VIII, at €300M | Sofinnova Partners, a Paris, France-based European venture capital firm specialized in Life Sciences, closed its latest fund, at €300m, above the initial fund target of €250m.
Sofinnova Capital VIII attracted premier international investors... |
| 24.11.2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| 23.11.2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| 16.11.2015 | BiovelocITA Launches to Accelerate Biotech Companies in Italy | Sofinnova Partners, a European venture capital firm specialized in Life Sciences, has just launched BiovelocITA, the first Italian accelerator dedicated to biotech companies.
Sofinnova and a restricted group of investors will also provide €... |
| 25.02.2015 | Comet Biorefining Closes Funding Round | Comet Biorefining Inc., a London, Ontario, Canada-based developer of cellulosic glucose technology, closed a funding round of undisclosed amount.
The round was led by Sofinnova Partners. In conjunction with the funding, Joško Bobanović, Sof... |
| 23.05.2014 | Lysogene Raises €16.5M in Series A Funding | Lysogene, a Paris, Germany-based gene therapy company, raised €16.5m in Series A funding.
The round was led by Sofinnova Partners, with participation from Bpifrance‘s Innobio fund and Novo Seeds, which is part of Novo A/S. In conjunction wi... |
| 04.04.2014 | RefleXion Medical Raises $11.6M Series A Funding | RefleXion Medical, a Burlingame, CA-based medical device company developing a biologically-guided radiation therapy system for cancer treatment, raised an $11.6m Series A funding round.
The round was led by Sofinnova Partners with participa... |
| 03.04.2014 | Crescendo Biologics Raises Further £2M in Series A Financing | Crescendo Biologics Limited, a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics, a raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing.
... |
| 27.01.2014 | Shockwave Medical Raises $12.5M in Series A Financing | Shockwave Medical, a Fremont, California-based developer of intravascular devices for patients with challenging calcified cardiovascular disease, raised $12.5m in Series A financing.
The round was led by Sofinnova Partners. In conjunction w... |
| 17.12.2013 | Crescendo Biologics Raises £17.5M in Series A Financing | Crescendo Biologics Limited, a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics, raised £17.5m ($28m) in a Series A financing.
The round was led by Imperial Innovations with par... |
| 02.12.2013 | Green Biologics Raises £15.4M in Series B Funding | Green Biologics Ltd, an Oxford, UK-based industrial biotechnology company, raised £15.4m in Series B funding.
The round was led by Sofinnova Partners with participation from Swire Pacific Limited, Capricorn Venture Partners, Oxford Capital ... |
| 04.11.2013 | Hookipa Biotech Raises €20M in Series B Equity Financing | Hookipa Biotech AG, a Vienna, Austria-based developer of a new class of vaccines, raised €20m ($27.5m) in Series B equity financing.
The roud was led by existing investors Sofinnova Partners and Forbion Capital Partners with participation f... |
| 29.08.2013 | ObsEva Closes CHF32M Series A Financing | ObsEva, a Geneva, Switzerland-based biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine, closed a CHF32m (approximately €25.6m) Series A financing round.
The round was led by Sofinnov... |
| 29.08.2013 | ObsEva SA announces CHF 32 Million funding | |
| 17.04.2013 | Auris Medical Completes CHF47.1M Series C Financing | Auris Medical, a Basel, Switzerland-based biotechnology company that develops novel therapeutics for the treatment of inner ear disorders, completed a CHF47.1m Series C financing.
Backers included Sofinnova Ventures and Sofinnova Partners. ... |
| 16.04.2013 | Biggest Swiss financing round in 2013: CHF 47.1 mn for ground-breaking inner ear therapies | |
| 09.04.2013 | MedDay Raises €8M in Funding | MedDay, a Paris, France-based biotech company, raised €8m in funding.
Backers included InnoBio, a biotech fund managed by CDC Entreprises, and venture capital firm Sofinnova Partners.
The company intends to use the funding to finance the de... |
| 03.04.2013 | Aledia Raises €10M in First Financing | Aledia, a Grenoble, France-based developer of LEDs based on microwire GaN-on-Silicon technology, said it had raised €10m (approximately $13m) in its first financing.
Backers included Sofinnova Partners, Braemar Energy Ventures, Demeter Part... |
| 23.12.2012 | Fondo Italiano di Investimento Makes €15M investment in Sofinnova Capital VII | Fondo Italiano di Investimento recently made a €15m investment in Sofinnova Capital VII.
Sofinnova Capital VII is the seventh venture capital fund launched by Sofinnova Partners. With a final close of €240m (read here), the focuses on backi... |
| 23.12.2012 | Sofinnova Partners Raises €240M Life Sciences Venture Capital Fund | Paris, France-based Sofinnova Partners has raised €240m (approximately $312m) for its seventh venture capital fund dedicated to the life sciences.
Sofinnova Capital VII has received support from pension funds, fund of funds and insurance co... |
| 29.11.2011 | NuCana BioMed Closes £6.74M Series A Venture Funding | NuCana BioMed, an Edinburgh UK-based biopharmaceutical company focused on anti-cancer therapies, has closed a £6.74m (approximately $10.4m) Series A venture funding.
The round was led by Sofinnova Partners, with participation from Morningsi... |
| 26.10.2011 | Hookipa Biotech Raises €7M in Series A Financing | Hookipa Biotech, an Austrian biotech startup specialized in developing new generation vaccines, has raised €7m in Series A financing.
Backers include Forbion Capital Partners and Sofinnova Partners.
Founded in July 2011, Hookipa has develop... |
| 26.08.2011 | MISSION Therapeutics Raises £6M in Series A Funding | MISSION Therapeutics Ltd, a Cambridge, UK-based newly formed company that is developing a broad platform of technologies for the discovery and development of targeting enzymes involved in cancer and other diseases, has raised £6m in a Serie... |
| 10.06.2011 | Avantium raises $43 million for plant-based plastic | Avantium just raised $43 million (30 million EUR) from a group of investors including Sofinnova Partners, Aster Capital and De Hoge Dennen.
Avantium’s YXY technology enables the cost effective production of a 100 percent plant-based, recycl... |
| 17.02.2010 | OpenERP gets €3 million for US expansion | [Belgium] Belgium’s OpenERP has just received a €3 million investment from Sofinnova Partners, as well as Iliad co-founder and manager Xavier Niel and board member Olivier Rosenfeld. The funding will be used primarily to reinforce the manag... |
| 27.01.2010 | The $62 million sale of a touch tech startup adds to the Tablet revolution | Welcome to the Touch revolution. Ahead of the impending news about the iTablet/iPad from Apple today, comes news that a French maker of touch input technology has been acquired by Tyco Electronics for $62 million upfront. Motorola’s venture... |
| 26.01.2010 | France, Sofinnova Partners Closes $260M Venture Capital Fund | Sofinnova Partners, a Paris, France-based venture capital firm, closed its sixth fund, Sofinnova Capital VI, raising €260m.
Investors in Sofinnova Capital VI include CDC Entreprises, Industrial & Financial Investments Co., JP Morgan Ass... |
| 16.10.2009 | Flexion Therapeutics Raises $33M in Series A Financing | Flexion Therapeutics, a Woburn, Mass.-based company that advances drug candidates through clinically meaningful proof of concept and beyond, completed a $33m Series A financing round led by Versant Ventures with participation from founding ... |
| 13.02.2009 | TechCrunch Roundtable At Mobile World Congress: Mobile 2.0 – Where Next? | TechCrunch is hosting a Roundtable and Meetup at Mobile World Congress on Thursday next week. “TechCrunchTalk: Mobile 2.0 – Where next?” at Mobile World Congress in Barcelona will feature an afternoon of panel discussions and some great eve... |
| 05.09.2008 | mydeco Secures Significant Investment to Fund International Launch | LONDON, UK September 5, 2008– mydeco, the online intermediary for the home design market, today announced that it has secured £7.35M in its second round of funding. Sofinnova Partners, one of Europe’s leading venture capital firms, led the ... |
| 26.02.2008 | Sofinnova Becomes a Shareholder of PC30 | The investment will accelerate the young company’s international development
Paris, France — 26 February 2008 — Sofinnova Partners, the French venture capital firm premier among the top European firms, announced shareholder participation in... |
| 21.07.2007 | GlycoVaxyn pulls in $9.3M for conjugated vaccines | Zurich’s GlycoVaxyn, a biotech developing new “conjugated vaccines”, raised a $9.3 million first funding round. Sofinnova Partners and Index Ventures supplied the investment.
The company will use the funding to push forward with the develop... |
| 03.05.2007 | Noxxon Pharma draws $50M for aptamer drugs | Noxxon Pharma, a Berlin-based biotech, raised 37 million euros ($50 million) to help push its first aptamer-based drug candidates for kidney and eye disease into clinical trials.
The main new investors included TVM Capital, Sofinnova Partne... |
| - | Sofinnova Partners Closes €445M ($540M) Oversubscribed Late-Stage Healthcare Crossover Fund | PARIS--(BUSINESS WIRE)--Mar 3, 2021--
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of the Sofinnova Crossover Fund at €445 million ($540 million ... |
| - | Sofinnova Partners raises $548m for tenth healthcare venture fund | - |
| - | Sofinnova Partners launches a €300M biotech startup fund with European focus | Paris-based venture capital firm, Sofinnova Partners, has closed its Sofinnova Capital VIII fund with €300 million ($324 million) that will be dedicated toward adding 15 to 20 more biotech companies to its portfolio, two thirds of which wil... |
